In contrast, for patients with an existing diagnosis of HF at trial enrollment, we believe added prospective data collection at baseline is imperative to best explore the impact of therapy in various HF subsets based on EF, baseline HF therapy, and severity of disease
In contrast, for patients with an existing diagnosis of HF at trial enrollment, we believe added prospective data collection at baseline is imperative to best explore the impact of therapy…